I am skeptical of the validity of the data provided by Eli Lilly, as it may be subject to bias. A comparative study conducted by Novo Nordisk would offer a more objective assessment. Furthermore, Wegovy has been shown to possess certain cardiovascular advantages.
Insurance does dictate. One year Ozempic is covered, the next year it’s not and they’re forcing you to switch to Mounjaro. I don’t know if it’s a supply issue or some monetary deal the insurance has with the drug maker.
I am skeptical of the validity of the data provided by Eli Lilly, as it may be subject to bias. A comparative study conducted by Novo Nordisk would offer a more objective assessment. Furthermore, Wegovy has been shown to possess certain cardiovascular advantages.
Insurance does dictate. One year Ozempic is covered, the next year it’s not and they’re forcing you to switch to Mounjaro.
I don’t know if it’s a supply issue or some monetary deal the insurance has with the drug maker.